Abstract No. 119: Novel Iron Oxide Nanoparticle-Mediated Transcathether Intraarterial Delivery of Doxorubicin to Liver Tumors in the VX-2 Rabbit Model: a Dose-Escalation Study
T.O. Lawal,V. Prieto,H. Mao,H.S. Kim
DOI: https://doi.org/10.1016/j.jvir.2011.12.161
IF: 3.682
2012-01-01
Journal of Vascular and Interventional Radiology
Abstract:To investigate the feasibility and safety of transcatheter intraarterial drug delivery of novel doxorubicin encapsulated iron oxide nanoparticles to VX-2 rabbit liver tumor model. Paramagnetic iron oxide (IO) nanoparticles (core and hydrodynamic size of 10 and 23 nm) coated with amphiphilic polymers were mixed with hydrophobic doxorubicin molecules, and their presence within the nanoparticles was confirmed by optical absorption spectrum. New Zealand White rabbits with VX-2 tumors implanted in the liver were treated when a 2.0 cm lesion was visible on MRI. Group A received image-guided intraarterial transcatheter delivery of doxorubicin encapsulated IO nanoparticles to the hepatic artery, and group B received intravenous injection through the marginal ear vein. Doxorubicin treatment concentrations ranged from 0 to 1.0 mg/ kg. Rabbits were closely monitored for toxicity or any complications for the study duration. Blood samples were collected at intervals to analyze baseline liver function and to follow post treatment response up to 7 days. As doxorubicin concentration increased from 0, 0.4, 0.6, and 1.0 mg/kg, rabbits receiving IA or IV nanoparticle therapy had no significant changes in the pretreatment levels of LFTs and biomarkers compared to the 1 hour, 24 hour, and 7 day levels. Group A AST levels ranged from 81-119, 42-108, and 28-32 U/l; group B AST levels were between 52-71, 53-61, and 85-103 U/l (p=.0129). ALT levels in Group A ranged from 17-88, 19-70, 30-500, and 24-32 U/l; group B levels ranged from 25-40, 45-50, and 16-93 U/l (p=.923). BA in group A ranged from 5-16, 2-6, 4-6, and 5-8 U/l; group B was between 3-8, 4-10, and 4-8 U/l. Group A CHOL levels ranged from 40-68, 39-78, and 42-126; group B levels ranged from 32-57, 74-80, and 61-97. For all doxorubicin concentration increases, levels of GGT, BUN, ALB, and TBIL remained within a narrow range: GGT (5-9 IU/liter), BUN (8-16 mg/dl), ALB (1.0-2.2), and TBIL (0.1-0.3) in groups A and B (p<.001). Novel doxorubicin encapsulated iron oxide nanoparticles can be safely delivered intraarterially to the VX-2 rabbit liver cancer model at doses up to 1.0 mg/kg of doxorubicin.